<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0255">
 <label>50</label>
 <element-citation publication-type="journal" id="rf0245">
  <person-group person-group-type="author">
   <name>
    <surname>Anderson</surname>
    <given-names>L.J.</given-names>
   </name>
   <name>
    <surname>Dormitzer</surname>
    <given-names>P.R.</given-names>
   </name>
   <name>
    <surname>Nokes</surname>
    <given-names>D.J.</given-names>
   </name>
   <name>
    <surname>Rappuoli</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Roca</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Graham</surname>
    <given-names>B.S.</given-names>
   </name>
  </person-group>
  <article-title>Strategic priorities for respiratory syncytial virus (RSV) vaccine development</article-title>
  <source>Vaccine</source>
  <volume>31</volume>
  <issue>Suppl. 2</issue>
  <year>2013</year>
  <fpage>B209</fpage>
  <lpage>B215</lpage>
  <ext-link ext-link-type="uri" xlink:href="pmid:23598484" id="ir0330" xmlns:xlink="http://www.w3.org/1999/xlink">23598484</ext-link>
  <comment>PMCPMC3919153</comment>
  <pub-id pub-id-type="pmid">23598484</pub-id>
 </element-citation>
</ref>
